MedTrace Logo

Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

NCT06765161 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-07-29

No results posted yet for this study

Summary

This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.

Conditions

  • Myasthaenia Gravis

Interventions

DRUG

efgartigimod administration

efgartigimod infusion

Sponsors & Collaborators

  • argenx

    collaborator INDUSTRY

  • Clinique Neuro-Outaouais

    lead OTHER

Principal Investigators

  • François Jacques, Doctor · Clinique Neuro-Outaouais

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-06
Primary Completion
2027-01-06
Completion
2027-01-06

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06765161 on ClinicalTrials.gov